Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7.00
Bid: 6.75
Ask: 7.25
Change: 0.00 (0.00%)
Spread: 0.50 (7.407%)
Open: 7.00
High: 7.00
Low: 7.00
Prev. Close: 7.00
IXI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

11 May 2006 10:35

Phytopharm PLC11 May 2006 NOTIFICATION OF TRANSACTIONS OF DIRECTORS, PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY OR CONNECTED PERSONS This form is intended for use by an issuer to make a RIS notification requiredby DR 3.1.4R(1). (1) An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24. (2) An issuer making a notification in respect of a derivative relating to the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24. (3) An issuer making a notification in respect of options granted to a director/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24. (4) An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24. Please complete all relevant boxes in block capital letters. 1. Name of the issuer PHYTOPHARM PLC 2. State whether the notification relates to (i) a transaction notified in accordance with DR 3.1.4R(1)(a); or (ii) DR 3.1.4(R)(1)(b) a disclosure made in accordance with section 324 (as extended by section 328) of the Companies Act 1985; or (iii) both (i) and (ii) NOTIFICATION RELATES TO (iii) 3. Name of person discharging managerial responsibilities/director DR RICHARD DIXEY 4. State whether notification relates to a person connected with a person discharging managerial responsibilities/director named in 3 and identify the connected person AS 3 ABOVE 5. Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a non-beneficial interest 6. Description of shares (including class), debentures or derivatives or financial instruments relating to shares 7. Name of registered shareholders(s) and, if more than one, the number of shares held by each of them 8. State the nature of the transaction 9. Number of shares, debentures or financial instruments relating to shares acquired 10. Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage) 11. Number of shares, debentures or financial instruments relating to shares disposed 12. Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage) 13. Price per share or value of transaction 14. Date and place of transaction 15. Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage) 16. Date issuer informed of transaction If a person discharging managerial responsibilities has been granted options by the issuer complete the following boxes 17. Date of grant 9 MAY 2006 18. Period during which or date on which it can be exercised 9 MAY 2009 TO 8 MAY 2016 19. Total amount paid (if any) for grant of the option NIL 20. Description of shares or debentures involved (class and number) 35,175 PHYTOPHARM PLC ORDINARY 1 PENCE SHARES 21. Exercise price (if fixed at time of grant) or indication that price is to be fixed at the time of exercise FIFTY SIX PENCE 22. Total number of shares or debentures over which options held following notification 473,614 23. Any additional information PERFORMANCE CRITERIA ARE BASED ON TOTAL SHAREHOLDER RETURN COMPARED TO COMPARATOR GROUPS ON THE THIRD ANNIVERSARY OF GRANT. NO OPTIONS VEST FOR BELOW MEDIAN PERFORMANCE AND 100% VEST FOR UPPER QUARTILE PERFORMANCE AND ABOVE WITH PRO RATA VESTING BETWEEN MEDIAN AND UPPER QUARTILE PERFORMANCE. FOR 23,450 OPTIONS THE COMPARATOR GROUP COMPRISES 25 OTHER UK LISTED BIOTECH COMPANIES AND FOR 11,725 OPTIONS THE COMPARATOR GROUP IS THE FTSE SMALL CAP INDEX 24. Name of contact and telephone number for queries ZOE MCGOWAN 01480 437697 Name and signature of duly authorised officer of issuer responsible for making notification Date of notification 11 MAY 2006 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
4th Dec 20187:00 amRNSFinal Results
4th Dec 20187:00 amRNSScope expanded with top 10 biopharma company
15th Oct 20187:00 amRNSPre-Close Trading Update
21st Sep 20184:46 pmRNSResult of General Meeting - Amended
21st Sep 201811:00 amRNSResult of General Meeting
11th Sep 20187:00 amRNSContract with top 10 global pharmaceutical company
3rd Sep 20187:00 amRNSProposed Capital Reorganisation
30th Aug 20187:00 amRNSContract expansion with biopharmaceutical company
21st Aug 20187:00 amRNSTrading Statement
13th Aug 20187:00 amRNSAgreement
13th Jun 20189:00 amRNSImplementation of Long Term Incentive Plan
12th Jun 20187:00 amRNSNotification of the cessation of a clinical trial
7th Jun 20189:47 amRNSIssue of Equity
31st May 20183:32 pmRNSHolding(s) in Company
31st May 20183:30 pmRNSHolding(s) in Company
30th May 201811:48 amRNSHolding(s) in Company
30th May 201811:45 amRNSHolding(s) in Company
30th May 20189:32 amRNSDirector/PDMR Shareholding
29th May 201812:08 pmRNSResult of General Meeting
23rd May 20183:29 pmRNSDirector/PDMR Shareholding
23rd May 20187:00 amRNSHalf-year Report
14th May 20187:00 amRNSNew contract with top 10 pharmaceutical company
10th May 20187:00 amRNSExpansion of two biopharmaceutical contracts
3rd May 20187:00 amRNSNotice of Interim Results
3rd May 20187:00 amRNSPlacing to raise ?5.5 million
4th Apr 20187:00 amRNSAgreement
30th Jan 20187:00 amRNSNew contract in progressive supranuclear palsy
22nd Jan 20183:16 pmRNSResult of AGM
22nd Jan 20187:00 amRNSAGM Statement and Board Changes
11th Dec 20177:00 amRNSFinal Results
28th Nov 20177:00 amRNSStrategic and Operational Update
16th Nov 20177:00 amRNSContract to Deploy Biosensors in Clinical Trial
19th Oct 201710:14 amRNSTrading Statement
4th Oct 20177:00 amRNSNew contract to support Phase II clinical trial
28th Sep 20177:00 amRNSNew contract in Huntington's disease
25th Sep 20177:00 amRNSNew Contract with Biopharmaceutical Company
5th Sep 20177:00 amRNSExtension of a 5 year contract
8th Aug 20174:23 pmRNSDirector/PDMR Shareholding
24th Jul 20177:00 amRNSExpansion of Collaboration with Biogen
18th Jul 20177:00 amRNSIXICO hosts Alzheimer Expert Symposium
5th Jul 20177:00 amRNSNew contract for imaging clinical trial services
22nd May 20177:00 amRNSHalf Yearly Report to 31 March 2017
16th May 20179:57 amRNSNotice of H1 Results
12th Apr 201712:41 pmRNSExercise of share options
29th Mar 20173:30 pmRNSDirector/PDMR Shareholding
29th Mar 20173:30 pmRNSDirector/PDMR Shareholding
29th Mar 20173:30 pmRNSExercise of Share Options
13th Mar 20177:00 amRNSIXICO signs US$1.5m contract
10th Mar 201710:00 amRNSTo present novel sleep measurement technology
9th Feb 20177:00 amRNSGrant of Share Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.